Meloxicam as an adjuvant to peginterferon-α-2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial. (Q50549620)

15 March 2018

title

Meloxicam as an adjuvant to peginterferon-α-2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial. (English)

1 reference

15 March 2018

1 reference

Tatehiro Kagawa

1

1 reference

15 March 2018

Sei-Ichiro Kojima

2

1 reference

15 March 2018

Koichi Shiraishi

3

1 reference

15 March 2018

Shunji Hirose

4

1 reference

15 March 2018

Yoshitaka Arase

5

1 reference

15 March 2018

Shinji Takashimizu

6

1 reference

15 March 2018

Norihito Watanabe

7

1 reference

15 March 2018

Naruhiko Nagata

8

1 reference

15 March 2018

Makoto Numata

9

1 reference

15 March 2018

Hirokazu Shiozawa

10

1 reference

15 March 2018

Yasuhiro Nishizaki

11

1 reference

15 March 2018

Mayu Toki

12

1 reference

15 March 2018

Teruji Sugita

13

1 reference

15 March 2018

Kijuro Nomura

14

1 reference

15 March 2018

Takashi Sakaguchi

15

1 reference

15 March 2018

Kazuhiro Atsukawa

16

1 reference

15 March 2018

Hiroto Tajima

17

1 reference

15 March 2018

Yoshihiro Tei

18

1 reference

15 March 2018

Tsutomu Inomoto

19

1 reference

15 March 2018

Tetsuya Mine

20

1 reference

15 March 2018

publication date

29 January 2013

1 reference

15 March 2018

published in

Hepatology Research

1 reference

15 March 2018

volume

43

1 reference

15 March 2018

page(s)

925-932

1 reference

15 March 2018

issue

9

1 reference

15 March 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

cites work

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Nonsteroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Interferon-alpha combined with ketoprofen as treatment of naïve patients with chronic hepatitis C: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Interferon-alpha 2b combined with daily ketoprofen administration improves virological response in chronic hepatitis C: a prospective and randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naive chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

IFNalpha activates dormant haematopoietic stem cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Platelet sparing effect of COX II inhibition used with pegylated interferon alfa-2a for the treatment of chronic hepatitis C: a short term pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12046

21 January 2018

Identifiers

DOI

10.1111/HEPR.12046

1 reference

15 March 2018

PubMed ID

23356876

1 reference

15 March 2018